President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
The order comes after concerns have been raised about the security of access to contraception since bans on abortion have come into play and the Supreme Court ruling overturning Roe v Wade in 2022.
The aim of the order is to increase avenues for women to gain access to contraception, and to decrease costs associated, as reproductive rights advocates have been campaigning highlighting the barriers women are facing in acquiring contraception, leaving millions of women vulnerable and without contraception.
The ruling could help to encourage private health insurance agents to offer broader coverage and contraception options, such as covering multiple products and increasing efficiency in the process of obtaining appropriate care, all coming under the Affordable Care Act.
The order will also mean increased access to over the counter contraception, increase coverage of contraception through Medicare, promote family planning services through Medicaid, support access to contraception to vulnerable groups and students, and to further research and data collection on contraception access across the USA.
"This action will build on the progress already made under the Affordable Care Act by further reducing barriers that women face in accessing contraception prescribed by their provider," a White House fact sheet on the order proclaimed.
“Today’s announcements build on actions that the Biden-Harris Administration has already taken to protect access to contraception, including in response to two prior Executive Orders directing actions to safeguard access to reproductive health care services” stated the fact sheet.
In 2022, the US House of Representatives, which was largely controlled by the Democratic party at the time, passed a bill to request a law with the aim of protecting women’s access to contraception. However, on consideration by the Senate, the bill was eventually blocked from passing into law by Republican representatives.
As recently as last week, two Senators moved to introduce a new bill to achieve better protection for access to contraception, for this bill to get passed, it will need to be signed off by Democratic-controlled Senate and the Republican-controlled House.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News CPHI Pharma Awards 2024: Meet the winners from the CPHI Celebration
This year we had a lot to celebrate, the 35th Anniversary of CPHI, and our esteemed award winners, of which we included two additional categories this year, the Future Leader award, and Woman of the Year award. -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News Women in Pharma: C-Suite Journeys in Leading Diversity
In this CPHI Milan special of our monthly series, we sit down with our panel of C-suite executives speaking on the ‘Leading with Diversity: The CEO Journey’ panel at this year’s show. -
News Women in Pharma: A leader's approach to diversity advocacy
In our monthly series on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Mentorship Programme - building a stronger pharma community
CPHI has a reputation for bringing the pharma industry together, creating a space where partnerships can be formed and nurtured, and relationships can be developed and cultivated between all industry actors. These collaborations encourage growth in the... -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance